# Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

> **NCT03207178** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Longyao Biotechnology Inc., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Recurrent or Refractory B Cell Malignancy

## Interventions

- **BIOLOGICAL:** Mixed CD19/CD20 CAR-T Transfer

## Key facts

- **NCT ID:** NCT03207178
- **Lead sponsor:** Shanghai Longyao Biotechnology Inc., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2019-02-28
- **Final completion:** 2020-02-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207178, "Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03207178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*